Atlassian (TEAM) Positioned With Sound Fundamentals

Atlassian Corporation (NASDAQ:TEAM) is one of the 10 beaten-down technology stocks that could bounce back in 2026.

On February 9, Fatima Boolani from Citi reduced the firm’s price target on Atlassian Corporation (NASDAQ:TEAM) from $210 to $160. The analyst maintained her Buy rating on the shares, with more than 101% upside potential in the offering, despite a downward revision to the price target.

Boolani’s target reduction came in due to broader volatility within the software segment. However, following the company’s second quarter results, she noted that Atlassian’s underlying business metrics remain “sound.”

On February 6, the price target for Atlassian Corporation (NASDAQ:TEAM) was decreased from $230 to $185 by Canaccord analyst David Hynes. The analyst also maintained his Buy rating on the stock, which still offers a revised upside potential of almost 133%.

Hynes noted the company’s recent results announcement, which reported 26% growth in cloud revenue and outperformed the 22.5% guidance. Consequently, management raised full-year cloud growth targets by 180 basis points. Despite the uptick, the company remains prudent regarding its assumptions for the latter half of the year.

Atlassian Corporation (NASDAQ:TEAM) delivers collaboration, project management, and IT service tools that help enterprises in integrating their teams through a subscription-based model. Some of its offerings include Jira, Confluence, Trello, and Loom. The company offers a broad set of solutions, including project management, document sharing, video communication tools, service management, and Chat & Agent capabilities.

While we acknowledge the potential of TEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 17 Biotechnology Stocks with More Than 50% Upside and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.